Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.25)
# 2,668
Out of 4,761 analysts
48
Total ratings
45.83%
Success rate
7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $14.88 | +41.13% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.47 | +2,040.87% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.93 | +543.64% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $56.07 | -35.79% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $13.15 | +280.23% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $47.91 | +233.96% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $11.66 | +243.05% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $42.59 | +146.54% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $57.75 | -53.25% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $92.25 | +8.40% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.16 | +2,214.81% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $0.60 | +2,908.02% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $288 | $4.97 | +5,694.77% | 2 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $0.97 | +16,394.85% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $14.88
Upside: +41.13%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.47
Upside: +2,040.87%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.93
Upside: +543.64%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $56.07
Upside: -35.79%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $13.15
Upside: +280.23%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $47.91
Upside: +233.96%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $11.66
Upside: +243.05%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $42.59
Upside: +146.54%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $57.75
Upside: -53.25%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $92.25
Upside: +8.40%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.16
Upside: +2,214.81%
Nov 5, 2019
Maintains: Buy
Price Target: $15 → $18
Current: $0.60
Upside: +2,908.02%
Aug 15, 2018
Maintains: Buy
Price Target: $264 → $288
Current: $4.97
Upside: +5,694.77%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $0.97
Upside: +16,394.85%